Sodium phosphate p 32 Intravenous and Tofacitinib Extended-Release Tablets
Determining the interaction of Sodium phosphate p 32 Intravenous and Tofacitinib Extended-Release Tablets and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: The concomitant use of bone marrow depressants and sodium phosphate P-32 may have additive myelosuppressive effects. MANAGEMENT: Patients should be monitored for excessive bone marrow suppression during treatment with sodium phosphate P-32. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms. References AnazaoHealth Corporation "P32 Sodium Phosphate. Available from: URL: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=735f92e3-cc92-4d9b-afe8-f935a685ee78" ([2012 Jun]):
Professional:MONITOR: The concomitant use of bone marrow depressants and sodium phosphate P-32 may have additive myelosuppressive effects.
MANAGEMENT: Patients should be monitored for excessive bone marrow suppression during treatment with sodium phosphate P-32. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.
- AnazaoHealth Corporation "P32 Sodium Phosphate. Available from: URL: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=735f92e3-cc92-4d9b-afe8-f935a685ee78" ([2012 Jun]):
Generic Name: sodium phosphate p32
Brand name:
Synonyms: Sodium phosphate p 32 (Intravenous)
Generic Name: tofacitinib
Brand name: Xeljanz, Xeljanz XR
Synonyms: Tofacitinib
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Sodium phosphate p 32 Intravenous-Tofacitinib Tablets
- Sodium phosphate p 32 Intravenous-Tofranil
- Sodium phosphate p 32 Intravenous-Tofranil injection
- Sodium phosphate p 32 Intravenous-Tofranil-PM
- Sodium phosphate p 32 Intravenous-Tol-Tab
- Sodium phosphate p 32 Intravenous-Tolazamide
- Tofacitinib Extended-Release Tablets-Sodium Phosphates
- Tofacitinib Extended-Release Tablets-Sodium Phosphates Enema
- Tofacitinib Extended-Release Tablets-Sodium Phosphates Injection
- Tofacitinib Extended-Release Tablets-Sodium Phosphates Oral Solution
- Tofacitinib Extended-Release Tablets-Sodium Phosphates Tablets
- Tofacitinib Extended-Release Tablets-Sodium Picosulfate, Magnesium Oxide, and Citric Acid Powder for Solution